Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11308859 | 0.85 | IDO1 (0.40) | IDO1HTTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18348140 | 0.81 | PYCR1 (0.40) | IDO1HTTMAPK1RECQLHDAC8 | |
| SCHEMBL29292701 | 0.81 | IDO1 (0.38) | IDO1NR4A2HTTCYP1A2CYP3A4 | |
| SCHEMBL12764490 | 0.81 | MAPK14 (0.41) | IDO1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16724088 | 0.81 | PYCR1 (0.40) | IDO1NR4A2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL10369113 | 0.81 | IDO1 (0.58) | IDO1NR4A2HTTCYP1A2CYP3A4 | |
| SCHEMBL6857571 | 0.79 | IDO1 (0.56) | IDO1NR4A2HTTCYP1A2CYP3A4 | |
| SCHEMBL15544341 | 0.79 | FFAR4 (0.44) | IDO1HTTCYP3A4MAPK1MAPT | |
| SCHEMBL12133275 | 0.78 | MRGPRX4 (0.43) | IDO1CYP3A4GAATDP1MRGPRX4 | |
| SCHEMBL10108789 | 0.78 | NOS3 (0.36) | IDO1HTTCYP3A4MAPTHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1960 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788353-B1 | CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS | Clarity Pharmaceuticals Ltd (AU) | 2022-05-18 | — | — | EP | claimed |
| EP-3053944-B1 | METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR | SHINETSU CHEMICAL CO (JP) | 2021-10-06 | — | — | EP | claimed |
| CN-108147972-B | Preparation method of vipatavir intermediate and analogue thereof | 成都西岭源药业有限公司 | 2020-07-10 | — | — | CN | claimed |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2019-03-26 | — | — | US | claimed |
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | claimed |
| EP-3330277-A2 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2018-06-06 | — | — | EP | claimed |
| US-9938314-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2018-04-10 | — | — | US | claimed |
| US-9822146-B2 | Process for the manufacture of degarelix and its intermediates | FERRING B.V. (NL) | 2017-11-21 | — | — | US | claimed |
| EP-2461805-B1 | SPECTINAMIDES AS ANTI-TUBERCULOSIS AGENTS | UNIV TENNESSEE RES FOUND (US) | 2017-11-01 | — | — | EP | claimed |
| EP-2231621-B1 | PROCESS FOR PREPARING N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | claimed |
| US-4826993-A | Substituted diazolidinones | ELI LILLY AND COMPANY (US) | 1989-05-02 | — | — | US | claimed |
| WO-1988006600-A1 | SUBSTITUTED ALKYLAMIDES OF TEICOPLANIN COMPOUNDS | GRUPPO LEPETIT S.P.A. (IT) | 1988-09-07 | — | — | WO | claimed |
| EP-0218099-A2 | Amides of teicoplanin compounds | GRUPPO LEPETIT S.p.A. (IT) | 1987-04-15 | — | — | EP | claimed |
| EP-0175323-A2 | Biologically active peptides, processes for preparing them and pharmaceutical compositions | FARMITALIA CARLO ERBA S.r.l. (IT) | 1986-03-26 | — | — | EP | claimed |
| US-4567162-A | ANIMAL GROWTH PROMOTERS | FARMITALIA CARLO ERBA (IT) | 1986-01-28 | — | — | US | claimed |
| EP-0134986-A2 | Biologically active heptapeptides, agents thereof and their use | FARMITALIA CARLO ERBA S.r.l. (IT) | 1985-03-27 | — | — | EP | claimed |
| US-4491541-A | Peptides | FARMITALIA CARLO ERBA | 1985-01-01 | — | — | US | claimed |
| US-4474765-A | Biologically active peptides | FARMITALIA CARLO ERBA S.P.A. (IT) | 1984-10-02 | — | — | US | claimed |
| US-4148788-A | Synthesis of thymosin α1 | HOFFMANN-LA ROCHE INC. (US) | 1979-04-10 | — | — | US | claimed |
| US-4089821-A | Synthesis of peptide amides | ARMOUR PHARMACEUTICAL COMPANY (US) | 1978-05-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | NT5C3B, CDA, RNGTT | IDO1 2991/4885NR4A2 2189/4885HTT 1504/4885 |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | NT5C3B, CDA, RNGTT | IDO1 2991/4885NR4A2 2189/4885HTT 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.